Considering The EU Launch Of Biosimilar For Remicade, Merck’s 2nd Largest Drug, Does The Company Face Meaningful EPS Decline In 2016?
Merck’s EPS Impact Due To Remicade Biosimilar Competition In 2016 Is Insignificant, < 2%
Have more questions about Merck? See the links below.
- What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas?
- What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years?
- How Has Merck’s Revenue Composition Changed In The Last 5 Years?
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)